| New techniques and strategies in drug discovery J Du, J Guo, D Kang, Z Li, G Wang, J Wu, Z Zhang, H Fang, X Hou, ... Chinese Chemical Letters 31 (7), 1695-1708, 2020 | 106 | 2020 |
| Small-molecule modulators of the hypoxia-inducible factor pathway: development and therapeutic applications Z Li, Q You, X Zhang Journal of Medicinal Chemistry 62 (12), 5725-5749, 2019 | 49 | 2019 |
| Click Chemistry-Based Discovery of [3-Hydroxy-5-(1H-1,2,3-triazol-4-yl)picolinoyl]glycines as Orally Active Hypoxia-Inducing Factor Prolyl Hydroxylase Inhibitors … Y Wu, Z Jiang, Z Li, J Gu, Q You, X Zhang Journal of Medicinal Chemistry 61 (12), 5332-5349, 2018 | 44 | 2018 |
| Discovery of nonquinone substrates for NAD (P) H: Quinone oxidoreductase 1 (NQO1) as effective intracellular ROS generators for the treatment of drug-resistant non-small-cell … X Wu, X Li, Z Li, Y Yu, Q You, X Zhang Journal of medicinal chemistry 61 (24), 11280-11297, 2018 | 39 | 2018 |
| An NAD (P) H: quinone oxidoreductase 1 responsive and self-immolative prodrug of 5-fluorouracil for safe and effective cancer therapy X Zhang, X Li, Z Li, X Wu, Y Wu, Q You, X Zhang Organic letters 20 (12), 3635-3638, 2018 | 34 | 2018 |
| The prolyl hydroxylase inhibitor roxadustat: Paradigm in drug discovery and prospects for clinical application beyond anemia K Su, Z Li, Y Yu, X Zhang Drug discovery today 25 (7), 1262-1269, 2020 | 32 | 2020 |
| Inhibition of the oxygen-sensing asparaginyl hydroxylase factor inhibiting hypoxia-inducible factor: a potential hypoxia response modulating strategy Y Wu, Z Li, MA McDonough, CJ Schofield, X Zhang Journal of medicinal chemistry 64 (11), 7189-7209, 2021 | 22 | 2021 |
| Discovery of clinical candidate (5-(3-(4-chlorophenoxy) prop-1-yn-1-yl)-3-hydroxypicolinoyl) glycine, an orally bioavailable prolyl hydroxylase inhibitor for the treatment of … X Zhang, Y Lei, T Hu, Y Wu, Z Li, Z Jiang, C Yang, L Zhang, Q You Journal of Medicinal Chemistry 63 (17), 10045-10060, 2020 | 19 | 2020 |
| Discovery of a potent and orally bioavailable hypoxia-inducible factor 2α (HIF-2α) agonist and its synergistic therapy with prolyl hydroxylase inhibitors for the treatment of … Y Yu, F Yang, Q Yu, S Liu, C Wu, K Su, L Yang, X Bao, Z Li, X Li, X Zhang Journal of Medicinal Chemistry 64 (23), 17384-17402, 2021 | 14 | 2021 |
| Photoactivatable prolyl hydroxylase 2 inhibitors for stabilizing the hypoxia-inducible factor with light Z Li, K Su, Z Jiang, Y Yu, Q You, X Zhang Journal of Medicinal Chemistry 62 (16), 7583-7588, 2019 | 13 | 2019 |
| In situ inhibitor synthesis and screening by fluorescence polarization: an efficient approach for accelerating drug discovery Z Li, Y Wu, S Zhen, K Su, L Zhang, F Yang, MA McDonough, CJ Schofield, ... Angewandte Chemie 134 (45), e202211510, 2022 | 11 | 2022 |
| Metal-free synthesis of 3, 3′-bisindolylmethanes in water using Ph 3 C+[B (C 6 F 5) 4]− as the pre-catalyst Z Zhang, L Ji, X Liu, Z Li, Y Lv, Z Jia, TP Loh Organic Chemistry Frontiers 9 (19), 5154-5159, 2022 | 9 | 2022 |
| Discovery of prolyl hydroxylase 2 inhibitors with new chemical scaffolds as in vivo active erythropoietin inducers through a combined virtual screening strategy Z Yu, Z Li, Q Yu, Z Wang, H Song, H Sun, R Fan, A Bi, J Zhang, X Zhang Chemical Biology & Drug Design 95 (2), 270-278, 2020 | 9 | 2020 |
| A small-molecule probe for monitoring binding to prolyl hydroxylase domain 2 by fluorescence polarisation Z Li, S Zhen, K Su, A Tumber, Q Yu, Y Dong, M McDonough, CJ Schofield, ... Chemical Communications 56 (91), 14199-14202, 2020 | 8 | 2020 |
| Tetrahydropyridin-4-ylpicolinoylglycines as novel and orally active prolyl hydroxylase 2 (PHD2) inhibitors for the treatment of renal anemia K Su, Z Li, L Zhang, S Fang, M Mao, Z Sun, X Zhang European Journal of Medicinal Chemistry 238, 114479, 2022 | 3 | 2022 |
